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INTRODUCTION 
Fluid bed processes were first developed for the 
chemical industry to achieve better drying efficiencies 
than obtained with existing technologies e. g with tray 
drying. Implementation of spray nozzles in the fluid bed 
equipment enabled granulation processes, resulting in 
porous agglomerates and, processed to tablets, 
facilitating fast dissolution. With the development of the 
bottom spray technology highly efficient coating and 
layering processes became possible. While in the 
beginning this technology was mainly used for tablet 
coating, more and more processes were developed for 
coating of smaller particles, i. e. multiparticulates like 
pellets, minitablets and powders (e. g. API crystals).  
Multiparticulate dosage forms consist of small discrete 
units with particle sizes of 100 – 2000 µm [1] showing 
a matrix structure (API implemented in the core) or 
being API layered. In case of pellets or minitablets, 
functional coatings can be applied, resulting in taste 
masking, gastroresistant coatings or other specific 
release profiles. Filling of multiparticulates into 
capsules or sachets and administration via sprinkling on 
liquids or food makes them attractive for patients who 
are not able to swallow monolithic dosage forms, as is 
the case for children or elderly. The possibility of 
administering different amounts of multiparticulates 
provides an opportunity for the development of 
individualized medicines. Also a compression into 
tablets is possible, orally disintegrating tablets (ODTs) 
release their discrete units in the stomach, ensuring a 
controlled drug release and less dependency on the 
gastric emptying. 
Glatt offers several batch-wise or continuous 
technologies for the production of multiparticulates, 
matrix or layered pellets. Process development and 
optimization can be performed with quality by design 
approaches, process monitoring and control by state of 
the art PAT tools. The presentation will give an 
overview about the recent and most prevalent 
manufacturing methods. 
BATCH FLUID BED TECHNOLOGIES 
WURSTER TECHNOLOGY 
The Wurster technology [Figure 1] is a classic fluid bed 
technology used for drug layering and (functional) 
coating of even very small multiparticulates and 
powders. The layering or coating liquid is sprayed 
concurrently with the fluidization air into the circulating 
fluid bed. The liquid is frequently and repeatedly applied 
as droplets on the substrate [Figure 1] in an environment 
of high heat transfer, finally resulting in a dense coating. 
Figure 1: Wurster technology, coating process (Glatt 
Pharmaceutical Services GmbH & Co. KG) 
CPSTM TECHNOLOGY 
The CPSTM technology [Figure. 2] allows the 
preparation of both high drug loaded as well as low 
dosed matrix pellets, with sizes down to 150 µm. Based 
on advanced fluid bed rotor technology, the CPSTM 
technology works with a conical shaped rotating disc 
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and devices providing a directed product flow. No 
starting beads are required. The powder, containing API 
and typically microcrystalline cellulose is wetted by the 
pelletizing liquid until a pre-defined moisture level (and 
with this: particle size) is obtained. Due to centrifugal 
forces, spherical particles are formed and densified, 
characterized by smooth surfaces, narrow particle size 
distribution [Figure 3] and low porosity and attrition.  
Figure 2: CPSTM technology, pelletizition process (Glatt 
Pharmaceutical Services GmbH & Co. KG) 
Figure 3: Matrix pellets produced with CPSTM 
technology (left), and MicroPxTM technology (middle, 
and right, Glatt Pharmaceutical Services GmbH & Co. 
KG) 
CONTINUOUS FLUID BED TECHNOLOGIES 
MICROPXTM / PROCELL TECHNOLOGY 
The MicroPxTM technology is the preferred option for 
the production of high drug loaded pellets with API 
contents up to 95%. Spherical and smooth particles in 
the size of 150 µm or bigger can be obtained [Figure 3], 
exhibiting narrow particle size distributions. In this 
continuous process, the API containing liquid (solution, 
suspension, emulsion, melt [2]) is sprayed into the 
empty process chamber. Initially, fine powder is 
generated by spray drying, which is continuously 
agglomerated to seeds, and by further layering, to round 
pellets. Well-sized pellets are discharged by a sifter; the 
classifying air determines the resulting particle size. The 
process is characterized by a balanced ratio between 
spray drying, layering and discharging of well-sized 
pellets.  
In contrast to the MicroPxTM technology the process gas 
enters the process chamber in the ProCellTM not through 
an inlet air distribution plate, but through slots in the 
lower part of the equipment, resulting in a spouted bed 
[Figure 4]. The contact of the product to hot surfaces is 
minimized, therefore this technology is applicable also 
for heat sensitive substances like enzymes. 
Figure 4: MicroPXTM (left) and ProcellTM (right)
technology, pelletization process (Glatt Pharmaceutical 
Services GmbH & Co. KG) 
PROCESS CONTROL 
For the implementation of robust and reproducible 
production processes, the critical quality attributes for a 
manufacturing process shall be known [3]. After a risk 
analysis, a design of experiments (DoE) with planned 
trials is applied, to define the design space and a control 
strategy for selected process parameters. PAT tools e. g. 
for online measurement of moisture, API content and 
particle size distribution can be applied for automated 
end point detection, to reduce the offline control and 
release testing. 
SUBSCRIPT 
API Active pharmaceutical ingredient 
DoE Design of experiments 
ODT Oraly disintegrating tablet 
PAT Process analytical technology 
QbD Quality by Design 
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